BD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathway

@article{Liu2013BD750AB,
  title={BD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathway},
  author={Ying-xia Liu and Tai Yang and Hongliang Li and Min-hui Li and Jin Liu and Yantang Wang and Shu-xia Yang and J. Zheng and Xingyan Luo and Yi Lai and Ping Yang and Li-mei Li and Qiang Zou},
  journal={British Journal of Pharmacology},
  year={2013},
  volume={168}
}
A series of benzothiazole derivatives were screened for immunosuppressive activity; of these compounds BD750 was found to be the most effective immunosuppressant. The purpose of the current study was to determine the immunosuppressive activity of BD750 on T cell proliferation and its potential mode of action. 
PO‐322 exerts potent immunosuppressive effects in vitro and in vivo by selectively inhibiting SGK1 activity
TLDR
The mechanism(s) underlying the inhibition of T‐cell proliferation in vitro by PO‐322 is investigated, as well as its effects on the delayed‐type hypersensitivity (DTH) response and imiquimod‐induced dermatitis in vivo. Expand
A novel water-soluble benzothiazole derivative BD926 inhibits human activated T cell proliferation by down-regulating the STAT5 activation.
TLDR
Data suggest that BD926 may be a lead compound for the design and development of new immunosuppressants for the intervention of allograft rejection and autoimmune diseases. Expand
A novel water-soluble benzothiazole derivative BD926 triggers ROS-mediated B lymphoma cell apoptosis via mitochondrial and endoplasmic reticulum signaling pathways.
TLDR
BD926, a novel water-soluble benzothiazole derivative, is developed and it is shown that it could inhibit the proliferation and induce apoptosis of human Ramos B-lymphoma cells and triggered apoptosis through both mitochondria and endoplasmic reticulum pathways. Expand
A benzoxazole derivative PO‐296 inhibits T lymphocyte proliferation by the JAK3/STAT5 signal pathway
TLDR
Findings indicate that PO‐296 inhibits human activated T‐lymphocyte proliferation by affecting the janus kinase 3 (JAK3)/STAT5 pathway and possesses a potential lead compound for the design and development of new immunosuppressants for the treatment of autoimmune diseases. Expand
Stat5 gene dosage in T cells modulates CD8+ T‐cell homeostasis and attenuates contact hypersensitivity response in mice
TLDR
Contact hypersensitivity assay (CHS) faithfully models human allergies and addresses the role of Stat5 gene dosage in contact allergies. Expand
K313, a novel benzoxazole derivative, exhibits anti‐inflammatory properties via inhibiting GSK3β activity in LPS‐induced RAW264.7 macrophages
TLDR
Investigation of the anti‐inflammatory properties and the underlying molecular mechanism of K313 in lipopolysaccharide (LPS)‐induced RAW264.7 macrophages indicated that K313 exhibited anti‐ inflammation properties and revealed the potential mechanism. Expand
Benwamycins A-G, Trialkyl-Substituted Benzene Derivatives from a Soil-Derived Streptomyces.
Seven new trialkyl-substituted benzene derivatives named benwamycins A-G (1-7), together with three known congeners, 8-10, were isolated from culture broth of the soil-derived Streptomyces sp.Expand
Tolerogenic Dendritic Cells Induced by BD750 Ameliorate Proinflammatory T cell Responses and Experimental Autoimmune Encephalitis in Mice
TLDR
Treatment with BD750 induced tolDC that inhibited proinflammatory T cell immunity in vitro and in vivo and may be valuable for development of new therapies for EAE and other autoimmune diseases. Expand
Improvement of glucocorticoid‐impaired thymus function by dihydromyricetin via up‐regulation of PPAR&ggr;‐associated fatty acid metabolism
TLDR
DEX and DMY relieved thymus function damaged by DEX via regulation of PPAR&ggr;‐associated fatty acid metabolism and simultaneously enhance the anti‐inflammatory effect of DEX, and may provide a new strategy on protection of thymUS from damage caused by GCs by using appropriate adjuvant natural agents. Expand
Isochaetomium A2, a new bis(naphthodihydropyran-4-one) with antimicrobial and immunological activities from fungus Chaetomium microcephalum
Isochaetomium A2 (1), a new bis(naphthodihydropyran-4-one), along with chaetochromins A (2) and B (3), was isolated from the solid-state fermented rice culture of Chaetomium microcephalum. TheExpand
...
1
2
...

References

SHOWING 1-10 OF 51 REFERENCES
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
TLDR
Optimization within this chemical series led to identification of CP-690,550 1, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection. Expand
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
TLDR
It is believed JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clinical settings. Expand
Imidazo[2,1-b]benzothiazoles. 2. New immunosuppressive agents.
A series of 2-phenylimidazo[2,1-b]benzothiazole derivatives was prepared and tested for immunological activities. Some of the compounds showed significant suppressive activity of delayed typeExpand
Immunopharmacology of rapamycin.
TLDR
Accumulating data suggest that mTOR functions in a previously unrecognized signal transduction pathway required for the progression of IL-2-stimulated T cells from G1 into the S phase of the cell cycle. Expand
Novel Immunosuppression: R348, a JAK3- and Syk-Inhibitor Attenuates Acute Cardiac Allograft Rejection
TLDR
R348 is a promising novel JAK3/Syk-inhibitor with favorable pharmacokinetics and biological activity that effectively diminishes acute cardiac allograft rejection and is suitable for combination regimens with tacrolimus. Expand
JAK3 inhibitors in organ transplantation and autoimmune disease.
TLDR
This review would provide an overview of some patents along with the role of JAK3 in the immune system and efficacy of Jak3 inhibitors in experimental allograft rejection and autoimmune disease. Expand
Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.
TLDR
Observed interactions between CsA, FK-506, and rapamycin suggest that complexes formed between the drugs and their major binding proteins may affect the function of other, unidentified, molecules or, alternatively, that minorbinding proteins may play a role in the drugs' action. Expand
Synthesis of novel cinnamanilides as potential immunosuppressive agents.
A series of new cinnamanilides (6-40) were synthesized and their immunosuppressive activity and cytotoxicity were evaluated. Most of the cinnamanilides showed good immunosuppressive activity. AmongExpand
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
TLDR
The results suggest that calcineurin is involved in a common step associated with T cell receptor and IgE receptor signaling pathways and that cyclophilin and FKBP mediate the actions of CsA and Fk506 by forming drug-dependent complexes with and altering the activity of calcineURin-calmodulin. Expand
Therapeutic targeting of Janus kinases
TLDR
A great deal is learned about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings. Expand
...
1
2
3
4
5
...